Centessa Pharmaceuticals plc
CNTA
$39.60
-$0.02-0.04%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 16.21% | -50.50% | -46.41% | -61.72% | -56.04% |
| Total Depreciation and Amortization | -6.14% | -61.92% | -53.46% | -37.82% | 10.32% |
| Total Amortization of Deferred Charges | 192.50% | 925.00% | 307.09% | 103.57% | 20.00% |
| Total Other Non-Cash Items | -55.14% | 81.53% | 105.82% | 615.61% | 705.61% |
| Change in Net Operating Assets | -235.49% | 5.86% | 175.42% | 67.41% | 217.71% |
| Cash from Operations | -36.44% | -38.76% | 1.65% | -8.16% | 11.40% |
| Capital Expenditure | -991.18% | -480.65% | -125.35% | 58.02% | 79.88% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -1,435.93% | -1,365.24% | -2,245.55% | -772.40% | 124.68% |
| Cash from Investing | -1,438.57% | -1,360.67% | -2,227.34% | -769.59% | 124.62% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -19.99% | -95.04% | 87.47% | 1,064.86% | 1,656.08% |
| Repurchase of Common Stock | 9.91% | -66.23% | -155.23% | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -20.08% | -96.99% | 85.26% | 1,030.48% | 1,627.29% |
| Foreign Exchange rate Adjustments | -136.51% | 139.02% | -171.35% | -261.08% | 99.51% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -225.89% | -253.99% | -365.77% | 90.79% | 196.08% |